KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$27.00+0.00%
Price as of Jun 12, 2026
KALV growth
KalVista Pharmaceuticals, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +1359.4%
- EBITDA
- +75.3%
- EBIT
- +69.7%
- EPS
- +64.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- -27.3%
- EBITDA
- —
- EPS
- +60.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.1%
- EBIT
- +8.6%
- Net income
- +10.4%
- EPS
- +12.5%
- Free cash flow
- +45.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.